The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Etoposide and cytarabine as an effective and safe cytoreductive regimen for relapsed or refractory acute myeloid leukemia.
G. Nair
No relevant relationships to disclose
R. Karmali
No relevant relationships to disclose
S. A. Gregory
No relevant relationships to disclose
J. M. Shammo
No relevant relationships to disclose
H. C. Fung
No relevant relationships to disclose
A. Jimenez
No relevant relationships to disclose
P. Venugopal
No relevant relationships to disclose
M. L. Larson
No relevant relationships to disclose